Stifel Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $40
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and a price target of $40.
May 01, 2024 | 9:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Bradley Canino has initiated coverage on Cullinan Therapeutics with a Buy rating and set a price target of $40.
The initiation of coverage by Stifel with a Buy rating and a high price target of $40 is likely to generate positive sentiment among investors, potentially driving up the stock price of Cullinan Therapeutics in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100